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Abstract
Background: The potential for transmission of blood-borne pathogens such as hepatitis B virus
from infected healthcare workers to patients is an important and difficult issue facing healthcare
policymakers internationally. Law and policy on the subject is still in its infancy, and subject to a
great degree of uncertainty and controversy. Policymakers have made few recommendations
regarding the specifics of practice restriction for health care workers who are hepatitis B
seropositive. Generally, they have deferred this work to vaguely defined "expert panels" which will
have the power to dictate the conditions under which infected health care workers may continue
to practice.
Discussion: In this paper we use recent Canadian policy statements as a critical departure point
to propose more specific recommendations regarding disclosure of transmission risks in a way that
minimizes practice restriction of hepatitis B seropositive health care workers without
compromising patient safety. The range of arguments proposed in the literature are critically
examined from the perspective of ethical analysis.
Summary: A process for considering the ethical implications of the disclosure of the sero-status
of health care workers is advanced that considers the varied perspectives of different stakeholders.
Background
The ethical issues surrounding health care workers in-
fected with blood borne viruses and practice restrictions
has drawn increasing attention. [1–15]. Many of the anal-
yses have dealt exclusively or at least significantly with
the issue of disclosure of seropositivity as a means for in-
fected HCWs to continue to practice [3–9]. However,
most have focussed on HIV and have not adequately ad-
dressed the unique features of HBV, particularly its pre-
ventability and higher transmissibility, which
distinguish it from HIV.
Of the few papers which have focused on HBV-infected
HCWs, none have adequately addressed the issue of dis-
closure of seropositivity as a means for infected HCWs to
continue to practise. Ristinen and Mamtani advocate
disclosure of seropositivity as a means of allowing pa-
tients to participate in care, however, their discussion is
quite superficial and does not address all of the primary
Published: 25 October 2001
BMC Medical Ethics 2001, 2:4
Received: 26 September 2001
Accepted: 25 October 2001
This article is available from: http://www.biomedcentral.com/1472-6939/2/4
© 2001 Barrigar et al; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any non-com-
mercial purpose, provided this notice is preserved along with the article's original URL. For commercial use, contact info@biomedcentral.comBMC Medical Ethics 2001, 2:4 http://www.biomedcentral.com/1472-6939/2/4
stakeholders in the issue [2]. Blatchford et al discuss an
actual case of an HBV-infected dentist, and the results of
a survey of exposed patients. They also advocate disclo-
sure of seropositivity, but argue this primarily from the
patient's right to know perspective and do not address
the issues from the HCW's perspective [4].
Thus, what appears to be missing from the literature is a
comprehensive examination of disclosure of HCW sero-
positivity and its role in determining appropriate prac-
tice restrictions for HCWs infected with hepatitis B virus.
In this paper we review the arguments from the litera-
ture, including the interests of the at-risk patient, the in-
fected HCW, and the health care system. We attempt to
provide a comprehensive and practical approach to in-
cluding disclosure of seropositivity in a system of prac-
tice restriction for HBV-infected HCWs.
Epidemiology of HBV transmission
HBV is transmitted by percutaneous or permucosal ex-
posure to infectious body fluids, by sexual contact with
an infected person, and perinatally from an infected
mother to her infant [16]. It differs from other transmis-
sible pathogens in several important ways. First, it is
more highly transmissible than HIV or hepatitis C virus
(HCV). In fact, HBV may be transmitted from HCWs to
the patient despite full compliance with universal pre-
cautions and correct infection control procedures [17].
An estimated 240 to 2,400 transmissions occur per mil-
lion procedures by an HBV-infected HCW compared to
2.4 to 24 per million transmission rate by an HIV-infect-
ed HCW [17]. Chronic carrier status is identified serolog-
ically by a positive hepatitis B "surface" antigen (HBsAg)
titre. Although it was once thought that only individuals
testing positive for hepatitis B "envelope" antigen
(HBeAg) in addition to HBsAg were at risk of transmit-
ting the infection, it is now known that surgeons who are
carriers of HBV without detectable levels of serum
HBeAg can transmit HBV to patients during procedures
[18]. Seroconversion rates after exposure to the virus in
a non-immunized individual range from 19–30% if the
source person is HBeAg positive and 5% if the source
person is HBeAg negative [17].
In terms of prevalence of HBV infection among HCWs,
data from the most recent U.S. National Health and Nu-
trition Examination (NHANES) did not show an in-
creased prevalence of chronic HBV infection among
adults with a medical occupation as compared to the rest
of the sample. However the NHANES study did not sep-
arate out specialities within medicine, e.g. surgeons,
where there may be a higher prevalence of HBV infec-
tion. This study estimated a prevalence of HBV infection
in the U.S. population of 5.5%, with 0.33% being chroni-
cally infected, in the period between 1976 and 1980 com-
pared to 4.9%, with 0.42% being chronically infected,
between 1988 and 1994[19].
Besides its high transmissibility relative to HCV and
HIV, HBV also differs in its preventability by immuniza-
tion. In Canada, this consists of 3 intramuscular doses of
a recombinant vaccine, administered in a series of 3 in-
jections over 6 months (at 0, 1 and 6 months), with a 95–
99% protective immune response observed among pedi-
atric and young adult populations [20]. Immune re-
sponse to the vaccine series is lower in adults over age 40
and immunocompromised individuals [20]. Fractionat-
ed anti-HBs immunoglobulin (HBIG) is often used in
combination with the vaccine series for post-exposure
prophylaxis, however, there is no consensus as to how
much additional protection, if any, it offers [16].
It is also important to know that hepatitis B is endemic to
many developing countries. The vast majority of chronic
carriers worldwide are individuals who were born in ar-
eas of high endemicity (i.e., where ≥  8% of the population
is HBsAg-positive) and who contracted the virus during
early childhood or perinatally, i.e., via vertical transmis-
sion from mother to neonate [21]. For example, in East
Asian, Southeast Asian and Pacific Island countries, 35
to 50% of HBsAg-positive women are also HBeAg-posi-
tive. If a mother is HBeAg-positive, her infants have a 70
to 90% risk of becoming infected if they do not receive
immunoprophylaxis at birth, which is not routinely
available in most countries where the virus is endemic.
Forty-five per cent of the world's population live in areas
of high endemicity which include Africa, most of Asia
(except Japan and India), most Pacific Island groups,
most of the Middle East, the Amazon Basin of South
America, and areas inhabited by special populations
such as native Alaskans, Australian aborigines, and New
Zealand Maoris [21].
In summary, HBV differs from other transmissible path-
ogens such as hepatitis C and HIV by virtue of its higher
transmissibility, its preventability, and its endemicity to
many developing countries.
Current policy on practice restrictions for HBV-
infected health care workers
The Laboratory Centre for Disease Control (LCDC) of
Health Canada recently issued recommendations for
health care institutions and individual HCWs regarding
transmission of bloodborne pathogens to patients by in-
fected HCWs [17]. The recommendations are advisory in
nature but represent one of the most authoritative sourc-
es of guidance for Canadian physicians and their provin-
cial/regional licensing bodies. We will be focusing on the
recommendations regarding disclosure of risks to pa-
tients, but we will briefly outline the LCDC approach to-BMC Medical Ethics 2001, 2:4 http://www.biomedcentral.com/1472-6939/2/4
ward practice restrictions as this will provide the context
for the disclosure recommendations.
According to the LCDC recommendations, HCWs and
student HCWs who perform or will perform "exposure-
prone procedures" and who test positive for HBsAg
should be referred to an expert panel for assessment. If
they are HBeAg positive, they should also cease practice
immediately, whereas those who are HBeAg negative
may continue to practise pending the panel's assess-
ment. Those who refuse screening are presumed HBeAg
positive and treated as such. The expert panels are to be
established by the provincial and territorial regulatory
bodies, and are responsible for addressing the issue of
whether the HCW is safe to continue practising expo-
sure-prone procedures. The LCDC advises the expert
panel to consider factors such as the type of infection and
viral load; procedural techniques; skill and experience of
the HCW; evidence of prior transmission by the HCW;
the HCW's compliance with universal precautions and
other infection control practices; and the likelihood of
compliance with the practice recommendations. From
this list, it appears as if the LCDC expects the panel pri-
marily to perform a harm-benefit analysis based on the
individual circumstances. LCDC also recommends that
"relevant ethical principles" be considered in the deci-
sion making, but fails to provide further guidance in this
area.
The LCDC guidelines also address the protection of HCW
privacy and confidentiality. In the case of physicians,
their recommendations stipulate that the professional
regulating body be notified of the seropositivity of any
practising physician, and that others, including mem-
bers of the expert panel who will be making practice rec-
ommendations, should be given personal health
information "strictly on a "need to know' basis." Similar-
ly, the LCDC recommended steps to protect the infected
physician's identity when disclosure to patients was con-
sidered.
Since disclosure to patients is the focus of this paper, we
have provided the LCDC recommendations on disclosure
in full:
"1. Provided that the infected HCWs health status and
the exposure-prone procedures have been assessed by
the expert panel and all the panel's recommendations are
followed, disclosure of a HCWs infected status to pa-
tients before an exposure-prone procedure is carried out
is not required as a way of protecting patients from
blood-borne pathogens.
2. After a significant exposure from any HCW has oc-
curred, the patient must be notified that he/she was ex-
posed to the blood of a member of the HCW team (the
HCW does not need to be identified by name).
3. The HCW has an obligation to be tested following a
significant exposure to the patient. If the HCW tests pos-
itive for HBV, HCV or HIV the patient has the right to
know to which pathogen he/she was exposed in order to
access the appropriate post-exposure protocol."
It is worthwhile knowing the policy positions of other
professional associations in order to serve as a compari-
son to the LCDC recommendations on practice restric-
tion and disclosure to patients. The Canadian Medical
Association (CMA) policy recommends that "physicians
who test positive for HBsAg cease activities of their prac-
tice that could expose patients to their body fluids until
their practice has been reviewed by an expert committee"
[22]. In terms of practice restriction, the final decisions
are left up to the expert committee, but the CMA offers
some guidance for achieving this. In particular, the CMA
recommends if HBV infectivity could not be reduced to
"acceptable levels", the physician's practice should be re-
stricted by directing the physician.
"to practise only on immune or infected patients when
his or her body fluids could come into contact with those
of the patient; and in the event the patient's immune sta-
tus is unknown, not to practise specified procedures dur-
ing which his or her body fluids could intermingle with
those of the patient"[22].
The CMA does not define what it considers "acceptable
levels" of infectivity. For comparison sake, the U.S. Cen-
tre for Disease Control (CDC) issued recommendations
in 1991 which differ from the LCDC recommendations on
the topic of disclosure to patients [23]. These recommen-
dations stated that
"HCWs who are infected with HIV or HBV (and are
HBeAg positive) should not perform exposure-prone
procedures unless they have sought counsel from an ex-
pert review panel and been advised under what circum-
stances, if any, they may continue to perform these
procedures. Such circumstances would include notifying
prospective patients of the HCW's seropositivity before
they undergo exposure-prone invasive procedures."
These CDC guidelines have been subject to much criti-
cism, and we will be examining those critiques before
recommending a policy regarding practice restriction
and disclosure of seropositivity which could be applied to
either U.S. or Canadian health care systemsBMC Medical Ethics 2001, 2:4 http://www.biomedcentral.com/1472-6939/2/4
Discussion
Ethical problems with the LCDC recommendations on dis-
closure to patients
It is worthwhile pointing out some concerns with the
LCDC's general approach to practice restrictions. First,
the current recommendations leave too much discretion
in the hands of the elusive expert panels. More detailed
guidelines with regard to practice restriction would do
more to ensure that infected HCWs are treated according
to a fair process, and are not as vulnerable to the partic-
ular biases and experiences of the members of the expert
panel overseeing their case. As well, a New Jersey court
case involving a surgeon with AIDS drew attention to the
conflict of interest of colleagues sitting on such a com-
mittee [3]. Their judgement may be influenced by fears
of becoming infected themselves at some point in their
career.
As for the LCDC recommendations on disclosure of risks
to patients, they fall short of current legal requirements
for informed consent and have some other ethical draw-
backs as well. In terms of an ethical analysis of these dis-
closure recommendations, there are three parties whose
interests we must keep in mind: the infected HCW's in-
terests in keeping his/her career and in performing his/
her role to improve the health of patients, the patient's
interest in not contracting a potentially fatal infection,
and society's interest in maintaining an effective and af-
fordable health care system. This involves addressing
ethical arguments such as the HCW's right to privacy, the
HCW's right to freedom from discrimination, the duty of
HCWs to provide benefit for their patients and not do
them harm, and the patient's right to autonomy and in-
formed choice. In addition, the societal benefits and/or
burdens of any policy should also be considered. Any
policy recommendations should also be legally prudent.
The case for disclosure of serological status
The process of informed choice and its legal require-
ments have evolved with the purpose of enhancing and
protecting patient autonomy in medical decision-mak-
ing. Failure of physicians to disclose "material, special or
unusual risks" regarding a medical treatment or proce-
dure to which a patient consents may result in a battery
or negligence suit against the physician [3,7,24]. Risks
meriting disclosure are determined in Canadian courts
by what a "reasonable person in the patient's position"
would want to know in order to decide whether or not to
undergo a procedure. Risks of 1% or less have been
deemed "material" by Canadian courts if the conse-
quences are adequately serious that a reasonable person
in the patient's position would want to know those risks
before consenting to a procedure [7,24].
With regards to blood-borne pathogens in particular, an
Ontario court held that the risk (described in evidence as
"infinitesimally small') of contracting hepatitis through a
blood transfusion ought to have been disclosed in a 1989
case [7,24]. The risk of contracting HBV via an invasive
procedure when the serological status of the HCWs in-
volved is unknown can be calculated by multiplying the
prevalence of chronic HBV infection (0.42%) with the
risk of transmission (240–2,400 per million). This re-
sults in a transmission risk of between 1 and 10 per mil-
lion. Although very small, this risk is that of acquiring a
potentially fatal disease, and as such it would be very dif-
ficult to argue that it should not be disclosed to patients.
The manner of disclosing this risk will vary with each in-
dividual and it is difficult to know if a blanket statement
commonly used by HCWs such as "there is a 1% risk of
infection from this procedure" is adequate, or whether
they ought to specify the source of the infection. Acquir-
ing HBV as a result of an invasive procedure is certainly
a qualitatively different outcome than having one's re-
covery complicated by a superficial wound infection.
The more difficult question is whether HCWs who are
known to be HBV-seropositive ought to disclose their se-
rological status to patients prior to procedures. This
changes the risk of transmission from between 1 and 10
per million to between 240 and 2,400 per million. This
represents a 200-fold increase in risk but the absolute
risk is still less than one per cent. Disclosure of this in-
creased risk would enhance patient autonomy by allow-
ing individual patients to decide whether or not to have a
procedure performed by an infected HCW based on the
significance of the infection risk to the patient. For many
patients, e.g., a young patient undergoing a common and
widely available procedure, this risk will likely be consid-
ered very significant and they probably will choose to
have the procedure performed by someone else. Alterna-
tively, consider a terminally ill patient undergoing a pal-
liative procedure, for whom the risk of acquiring a blood-
borne pathogen with primarily long-term complications
may not be particularly significant. It may be more im-
portant, for example, for such a patient to have the pro-
cedure performed as soon as possible by an HCW with
whom they have a long-standing and trusting relation-
ship. These two scenarios are illustrative of the different
values patients may have, and offering patients the
choice of having a procedure performed by a known in-
fected HCW allows them to make a decision based on
their individual values and priorities.
Such an approach is legally prudent as well. In 1993 the
Maryland Court of Appeals, using a "reasonable patient"
disclosure standard similar to Canada's, ruled that a sur-
geon who was HIV seropositive did have a duty to warn
patients of his/her infected condition or refrain from op-BMC Medical Ethics 2001, 2:4 http://www.biomedcentral.com/1472-6939/2/4
erating upon them [7]. The ruling also stipulated pa-
tients could recover damages for their fear of acquiring
AIDS for the period of time between learning of the sur-
geon's seropositive status and receiving HIV-negative re-
sults. With the higher transmission rate of HBV by an
infected HCW to a patient, it is likely that courts would
require the same duty of HBV-seropositive HCWs.
Further, a 1991 Newsweek poll reported that 95% of the
American public wanted surgeons to be required by law
to tell their patients if they are HIV-infected [7,15]. Nine-
ty-four percent wanted disclosure from physicians and
dentists, and 90% wanted disclosure from all HCWs.
Thus, the seropositive status of HCWs and the risk it pos-
es to patients is something that "reasonable" patients
want to know.
Thus, from the perspectives of promoting patient auton-
omy and doing what is legally prudent, there are very
strong cases in favour of infected HCWs disclosing their
serological status to patients as a requirement of per-
forming invasive procedures. However, there are ethical
challenges to such a disclosure policy which need to be
addressed. These come from two different camps – those
who argue that disclosure in and of itself is not sufficient
for protecting patients from significant transmission
risks and those who argue disclosure should not be re-
quired for infected physicians to continue to practise. We
will examine these arguments in turn.
The duty of health care workers to benefit their patients 
and do them no harm
All physicians and most other health care workers will at
some time in their life have heard the potent expression
"primum non nocere", which translated means "above
all, do no harm." This phrase is often quoted, but as
Beauchamp & Childress acknowledge, "its origins are ob-
scure and its implications unclear."[25] However, it pro-
vides the foundation for the ethical principle of
nonmaleficience, which "asserts an obligation not to in-
flict harm intentionally"[25].
In this vein, Tereskerz et al. argue that infected HCWs
not perform any procedures which present a risk of
transmission of blood-borne pathogens to patients and
that there be national policy involving lists of procedures
which health care workers with specific infections should
refrain from performing [3]. They do not consider disclo-
sure of transmission risk to patients an adequate meas-
ure for protecting patients, however they acknowledge it
to be a useful temporary measure to provide "limited"
protection for patients until a more ideal national policy
regarding practice restriction is put in place. They argue
that "patients may find it difficult to evaluate scientific
information concerning risk and may be reluctant to re-
quest an alternative physician when their own physician
is infected"[3]. Thus, on the basis of preventing patients
from harm, they propose quite strict practice restrictions
which would vary according to the specific pathogen with
which the health care worker was infected and the specif-
ic procedures to be performed.
While their proposal is noteworthy for its interest in pro-
tecting patients from harm, it may be overly paternalistic
when considering disclosure. Instead of allowing pa-
tients to determine for themselves what degree of risk
they are willing to accept, an expert committee would de-
cide what level of risk is acceptable to patients in the
course of deciding which procedures an infected HCW
may perform.
There are also other methods of preventing HBV trans-
mission which may be implemented instead of, or in ad-
dition to, practice restrictions. For example, surgical
patients could be offered immunization prior to elective
invasive procedures. This would have the added benefit
of protecting them from contracting HBV via other
modes of transmission, e.g. sexual contact or IV drug
use. Current costs of serological tests and vaccinations
may be considered prohibitive factors, but there are
enough proponents of universal HBV vaccination that
these costs should not be difficult to justify. HBV vacci-
nation is currently funded by provincial ministries of
health as part of child immunization programs (either as
infants or at 12 years of age), and is also offered by public
health units to individuals in high risk populations. Pro-
viding HBV vaccination routinely to surgical patients
would simply be an extension of a pre-existing public
health program.
It is also worth considering the HCW's own interests in
avoiding harm to their patients. Although there are cer-
tainly other benefits to be gained from a career in health
care, the majority of HCWs are at least partially attracted
to their profession by the desire to help people by im-
proving their health, well-being and/or quality of life.
Certainly most HCWs would feel at least some degree of
remorse if they learned they had transmitted HBV to one
of their patients. Surely, they would also want to avoid
the legal difficulties which would ensue.
In addition to the duties to provide benefit and do no
harm to patients, another important role of the HCW is
that of educator. Health care workers are generally re-
garded with respect by patients and often have the op-
portunity to serve as societal role models. If an HCW
were to reveal his/her own seropositivity in a positive
manner, this could help reduce the stigmas and fears as-
sociated with HBV and other infectious diseases.BMC Medical Ethics 2001, 2:4 http://www.biomedcentral.com/1472-6939/2/4
In summary, the combination of disclosing seropositivity
and offering vaccination to patients undergoing invasive
procedures sufficiently minimizes the harm to patients
to make this approach both ethically and legally accepta-
ble in terms of protecting patients' interests. It would
also contribute to the role of the HCW as healer and ed-
ucator. However, other important interests of health care
workers such as their right to privacy and freedom from
discrimination have yet to be addressed.
The discriminatory nature of a disclosure of serological 
status policy
Several authors have argued that infected HCWs should
not be discriminated against on the basis of their infec-
tive status [1,5,7,26]. Pinching is wary of restricting the
practice of infected HCWs, and points out "those profes-
sionals whose work puts them at most risk from blood-
borne infections from their patients are in effect regard-
ed as having lesser health rights if potential transmission
goes the other way"[26]. Norman Daniels considers the
conflict between patients' and HCWs' perceptions of
risks and discusses the distinction between objective and
subjective risk. On the one hand, he points out that pa-
tients' perceptions of transmission risks are likely to be
exaggerated, but respecting a patient's right to choose
which risks they will accept for themselves suggests we
accept patients' subjective perceptions of transmission
risks. "In contrast," he writes "the insistence on protect-
ing the rights of handicapped workers is intended to pro-
tect them against the exaggerated or fabricated
perceptions of fellow workers and employers; the ten-
dency is to insist that the significance of the risks they
impose on others be objectively determined [5]." Indeed
it is this tension between patients' and HCWs' interests
which is at the heart of this debate.
In Canada, legal protection against discrimination on the
basis of a "handicap" can be derived from the Charter of
Rights and Freedoms, the Canadian Human Rights Act,
and the provincial Human Rights Codes [7]. The provin-
cial codes are probably most important in this debate,
since they cover matters within provincial jurisdiction,
which includes most health care settings. Since at least
1992 the Ontario Human Rights Commission has inter-
preted protection against discrimination to extend to all
persons infected with HIV, including those who are
asymptomatic [7]. Flanagan summarizes the protection
from discrimination of HIV-infected workers under the
Ontario Human Rights Code as being legally binding un-
less
"1) the infected worker is reasonably likely to pose a seri-
ous risk to the health and safety of her patients; 2) this
risk is not similar to the other types of risks that are as-
sociated with the delivery of health care and generally
tolerated in society; and 3) even after accommodation
the remaining risk to the health or safety of her patients
outweighs the benefits of enhancing equality for the
HIV-infected HCW"[7].
Flanagan thus argues that although there is some risk as-
sociated with HIV-infected HCWs continuing to prac-
tice, this risk is extremely small and within the range of
risks society has long tolerated in the delivery of health
care.
Daniels and Gostin draw similar conclusions. However,
all authors were considering primarily the case of HIV-
infected HCWs. Does the 100-fold greater transmission
risk for HBV change their conclusions? Daniels quotes
risks of death due to general anaesthesia as 10 per mil-
lion, which by his data was 10 times greater than the risk
of being infected by a surgeon known to have HIV infec-
tion, but by newer data (2.4 to 24 per million) is roughly
equivalent. More importantly, what these authors do not
acknowledge is that routinely acceptable risks, such as
the risk of dying from anaesthetic use, are still disclosed
to patients even though the vast majority of patients are
willing to accept these risks. There will always be the rare
patient who will refuse surgical procedures with a high
cure rate because of their unwillingness to accept the low
risks of anaesthetic and surgical complications. There-
fore, this is not a good argument for not disclosing trans-
mission risks, especially since HBV is 100 times more
transmissible than HIV.
It should also be acknowledged that many HCWs who
are chronic carriers of HBV acquired the disease by vir-
tue of being born or spending their early childhood in a
region of the world with high prevalence of the virus.
Thus, restricting the practice of these HCWs represents a
degree of discrimination against people from certain re-
gions of the world or from special populations, such as
aboriginal groups. Barring entry to professional educa-
tional programs on the basis of HBV seropositivity pro-
vokes similar ethical debates, although they are beyond
the scope of this paper. Once again, the risks to patients
and coworkers need to be weighed against the negative
effects to the individual and the population group from
which he/she comes. Clearly, a policy which minimizes
practice restrictions for these HCWs without compro-
mising patient safety is preferable to a more restrictive
policy.
Privacy argument
Several authors consider another argument, which is
that the serological status of an infected HCW is infor-
mation which need not be disclosed to the patient be-
cause it is private information about the HCW [1,5,7].
They consider other factors affecting physician perform-BMC Medical Ethics 2001, 2:4 http://www.biomedcentral.com/1472-6939/2/4
ance such as stress, fatigue, medication side effects, fam-
ily problems, legal disputes, etc. which may affect
physician performance and cause harm to patients to the
same degree as representing a transmission risk of a
blood-borne pathogen. Do patients have a right to know
this type of private information about HCWs which
might affect their consent decision? What about other
private information such as the HCW's performance on
exams, history of malpractice suits, or substance abuse?
Presumably, HCWs performing far below the standard
level of care will be reported within their institution or to
their governing body enough times that corrective action
will be taken, but what about the majority of HCWs who
perform slightly below optimal performance? Like the
discrimination argument, the potential harm to patients
must be weighed against the invasion of the HCW's pri-
vacy and the resulting consequences to his/her practice.
The legal precedents here do not bode well for infected
HCWs wishing to keep their privacy. In a 1992 New Jer-
sey case, Behringer Estate v Princeton Medical Center, a
plastic surgeon with AIDS brought suit against the hos-
pital for invasion of privacy and breach of confidentiality
[3,27]. The hospital was informing patients of his illness,
and as a result his practice declined. The surgeon argued
the risk of transmission was too remote to be disclosed
and that the physical condition of the physician did not
need to be disclosed under the law of informed consent.
The court ruled in favour of the hospital, stating "physi-
cians performing invasive procedures should not know-
ingly place a patient at risk because of the physician's
physical condition"[27]. The court stated
"a reasonably prudent patient would find information
that his physician is infected with HIV material to his de-
cision to consent to a seriously invasive procedure be-
cause the potential harm is severe and the risk, while low,
is not negligible. Moreover, he can avoid the risk entirely
without any adverse consequences for his health: by
choosing another equally competent physician (where
available) he can obtain all the therapeutic benefits with-
out the risk of contracting HIV from his physician. The
patient, then can demonstrate not only that the informa-
tion is material to his decision, but that he would have
made a different decision had he been given the facts"
[28].
In summary, there seem to be sufficient legal precedents
in favour of disclosing the serological status of an infect-
ed HCW as part of informed consent for an invasive pro-
cedure. Perhaps there is some line that needs to be drawn
in terms of what personal information about the physi-
cian can be protected from patients, but if it has any
bearing on patient safety the courts will likely rule in fa-
vour of the patients, as they have in every case to date.
The only other form of legal protection would have to
come from statutory law, and it is difficult to foresee this
as a priority for legislators.
In ethical terms, it may be helpful to distinguish between
restrictions on an infected HCW's practice which are un-
fortunate vs those which are unfair. It would certainly be
considered unfortunate if a surgeon's vision was dam-
aged such that his/her operative complication rate went
up dramatically. Would it be considered unfair if this
surgeon's operating privileges were taken away? It would
be unfair if one surgeon's privileges were taken away for
this reason and another surgeon's privileges were un-
changed. The type of fairness being considered falls un-
der the theoretical term "formal" justice, and involves
treating like cases alike and treating different cases dif-
ferently [25]. The other type of fairness or justice that
should be considered is distributive justice, which in-
volves distributing the benefits and burdens of a policy or
decision equally among the different groups involved. It
certainly is unfair if infected HCWs bear all the burdens
of what is a public health problem, but we argue that this
unfairness is best remedied through compensatory
measures, i.e. retraining and/or financial compensation,
rather than putting patients at risk. Accordingly, the rec-
ommendations we propose below allow for an infected
HCW to continue to practise invasive procedures on sus-
ceptible patients only if he/she is willing to disclose his/
her seropositivity. If privacy is more important to the
HCW, then he/she should be given retraining and finan-
cial compensation opportunities. We should also re-
member that many HCWs have disability insurance
plans of some kind which are designed to make up a per-
centage of the lost income due to health reasons. Howev-
er, there are many HCWs, particularly physicians, who
do not have coverage, and not all plans will provide com-
pensation for entities such as HBV infection.
Systemic effects of disclosure vs non-disclosure
There are several utilitarian arguments to be made in fa-
vour of non-disclosure. Daniels argues "we get better
protection against HIV transmission by emphasizing in-
fection controls than we do by isolating and switching
from, or restricting the practice of, HIV-infected sur-
geons and other health care workers [5]." He argues re-
sources are more effectively utilized in the areas of
general infection control measures and epidemiological
research.
Daniels' arguments in this regard are very compelling.
Certainly measures taken to screen for and restrict the
practices of infected HCWs should not be at the expense
of education, improvements in infection control, and ep-
idemiological research. However, we know how much
the courts favour disclosure, thus we are obliged to con-BMC Medical Ethics 2001, 2:4 http://www.biomedcentral.com/1472-6939/2/4
sider the time and resources which would be lost in legal
disputes if disclosure did not occur. As well, it may be
practically difficult for a HCW to have imposed practice
restrictions and for them not to disclose to patients and
co-workers the reason for the restrictions. The resulting
rumours may end up being worse than the reality.
There are other systemic implications to be considered,
in particular, interference in the delivery of services.
Since risks to HCWs of contracting a blood-borne patho-
gen are higher than the risks to patients, more HCWs
may refuse to treat sero-positive patients [5,7]. They may
demand that patients be screened for blood-borne path-
ogens and risk factors prior to performing invasive pro-
cedures [5]. HCWs may also be less willing to undergo
serological testing if they fear the consequences of a pos-
itive result [26].
The current climate of uncertainty as to what happens to
HCWs who are discovered to be HBsAg-positive un-
doubtedly contributes to the fear that HCWs who per-
form invasive procedures must feel. The prospect of
having one's entire career and livelihood decided by an
"expert panel" with few governing guidelines is certainly
worthy of fear. If the guidelines were more directive and
allowed HCWs more opportunity to practice under con-
ditions which did not represent unacceptable compro-
mises for patients, this would likely relieve some of the
fear and anxiety amongst HCWs who perform invasive
procedures.
In summary, it is hard to clearly favour any policy ap-
proach over another in terms of utilizing the least re-
sources or causing the least interference in the delivery of
health care services.
What about retrospective disclosure?
A recent survey of patients in Scotland who had been in-
formed by letter of their exposure to a HBeAg positive
dentist provides support for retrospective disclosure of
exposure to a newly-discovered seropositive HCW [4].
The survey was mailed to a random sample of 528 pa-
tients representing 10% of the patients in 3 of the 4
health board areas, and 291 (55%) responses were re-
ceived. Ninety-three percent of respondents to this sur-
vey felt that patients should always be informed if they
have been treated by an infectious health care worker,
even if the risk was very small. Sixty-one percent of re-
spondents agreed they should have been informed by let-
ter, whereas 29% preferred to be informed in person.
In the discussion, Blatchford et al. refer to the Associa-
tion for Practitioners in Infection Control (APIC) ration-
ale for recommending retrospective patient notification
[29]. They state three purposes behind such exercises:
"1. It may enable patients infected by disease transmitted
from the health care worker to be identified.
2. Exposed patients may be offered a prophylactic medi-
cal intervention to reduce their risk of subsequently de-
veloping the disease.
3. Epidemiological studies to define the risk of transmis-
sion of disease from health care workers to patients may
be undertaken."
Blatchford et al. point out a deficit in the APIC statement
in that it does not consider the patient's right to informa-
tion as rationale for doing retrospective notification.
Although the patients can no longer make a decision
about undergoing the procedure performed by the in-
fected HCW, because this has already occurred, the in-
formation is important to them for making informed
decisions about the rest of their lives. They will need this
information to get the necessary screening to see if trans-
mission has occurred and follow-up to avoid complica-
tions if transmission has occurred. They should also be
educated about their risk of transmitting the infection to
others and associated prevention measures.
Arguments against retrospective notification of patients
are the time and costs involved, and the creation of un-
due anxiety, as only a small minority of patients notified
will have contracted the infection. However, if the pa-
tients discovered at a later date that they had been ex-
posed and not notified of the exposure, this would
certainly have deleterious consequences with regard to
their trust in the health care professions and the patient-
HCW relationship.
Recommendations for restricting the practice of HBV-in-
fected HCWs
What we propose below is a set of recommendations to
be considered by governing bodies when making deci-
sions about restricting the practice of HBV-infected
HCWs. These recommendations take into account the
relatively high transmissibility of HBV, the available
means of preventing HBV transmission, and the legal
and ethical arguments in favour of disclosure to patients
of transmission risks, including the elevated risks if an
involved HCW is known to be seropositive. The recom-
mendations do not mandate disclosure or non-disclo-
sure, but offer infected HCWs further opportunities to
practise invasive procedures without jeopardizing pa-
tient safety and autonomy if they are willing to relinquish
some privacy and reveal their seropositive status.
1. All patients undergoing exposure-prone procedures
should be informed of the risk of acquiring a blood-borneBMC Medical Ethics 2001, 2:4 http://www.biomedcentral.com/1472-6939/2/4
pathogen such as HBV during the procedure, regardless
of their HBV status. This should be disclosed as part of
the general pre-operative consent process, along with
other routine risks such as hemorrhage, wound infec-
tion, and anaesthetic risks.
2. All patients undergoing exposure-prone procedures
should be asked for documentation of a complete immu-
nization series or of positive HBsAg serology if previous-
ly performed. Patients with no such documentation
should be tested for protective antibodies as part of the
pre-operative workup. Patients who are not immune
should be offered the option of vaccination prior to un-
dergoing an elective or non-urgent procedure.
3. Physicians (or other HCWs) with known HBsAg sero-
positivity (regardless of their HBeAg status) should be
allowed to perform exposure-prone procedures on pa-
tients with documented immunity to HBV, either from
previous infection or from immunization. They need not
disclose their seropositivity to these patients, as the
transmission risk is no longer an issue.
4. HBV-seropositive HCWs may perform an exposure-
prone procedure on a patient who is not immune to HBV
provided the patient is a) informed of the elevated risk of
infection during the procedure due to the HCW's known
seropositivity, b) offered the services of a replacement
seronegative HCW to perform the procedure, and c) after
considering these options, the patient chooses to have
the procedure performed by the infected HCW.
5. When an HCW is discovered to test positive for HB-
sAg, all patients who underwent exposure-prone proce-
dures performed by the HCW should be traced and
notified of their now elevated risk of having contracted
HBV during the procedure. They should be offered sero-
logical testing and counselling. This process should be a
public health responsibility, and not the responsibility of
the infected HCW.
It should be noted that these recommendations may not
be practical for student HCWs who are HBV seroposi-
tive. It will be more difficult for these to keep their sero-
positivity confidential as they rotate frequently through
different services. A large number of people would need
to know the practice restrictions which apply to them in
order to avoid putting non-immune patients at risk of
contracting HBV. As well, disclosure opportunities to pa-
tients would be more difficult, since students are often
requested to assist in procedures with minimal advance
notice, and students do not have the same type of rela-
tionship with patients as staff HCWs.
Summary
Hepatitis B vims is unique amongst transmissible patho-
gens due to its high transmissibility and its preventabili-
ty, and therefore ethically and legally acceptable practice
restrictions for HBV-infected HCWs are not necessarily
equivalent to those for HIV- or HCV-infected physicians.
Policy regarding practice restriction of HBV-infected
HCWs should take into account the interests of patients,
HCWs and the implications of any policy to the health
care system at large. The current policy in Canada leaves
too much discretion in the hands of vaguely defined ex-
pert panels, and is likely contributing to fear and anxiety
amongst HCWs who are at risk of acquiring and trans-
mitting infectious pathogens. Providing vaccination
against HBV to patients undergoing elective procedures
reduces transmission risks and complements existing
vaccination programs. Allowing HBsAg-positive HCWs
to practise without restrictions on patients who have al-
ready been infected with or vaccinated against HBV-
would allow these HCWs to continue their career with
minimal interference. This also avoids undue discrimi-
nation against these HCWs. The option for these HCWs
to disclose their seropositivity to susceptible patients
provides an opportunity for patients to choose what risks
they are willing to accept in the course of their health
care, for HCWs to educate their patients about infectious
diseases such as HBV, and for infected HCWs to perform
more exposure-prone procedures. Retraining and finan-
cial compensation should be available for those HCWs
who choose not to disclose.
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